Enterprise Therapeutics Ltd announced that it has received £26 million in a round of funding led by new investor, Panakès Partners SGR SpA on January 30, 2024. The transaction included participation from returning investors, Versant Venture Management, LLC, Novartis Venture Fund, a fund managed by Novartis Venture Funds, Forbion Capital Partners B.V., Epidarex Capital and IP Group Plc. As part of the transaction, Rob Woodman of Panakès Partners SGR SpA joined the board of directors of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.85 GBX | +3.39% | +5.28% | -15.92% |
Apr. 23 | Alphawave confident in long term growth potential as revenue rises | AN |
Apr. 16 | Alphawave shares plunge as set to miss annual sales guidance | AN |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.92% | 628M | |
-6.03% | 113B | |
-3.98% | 87.91B | |
+20.42% | 63.85B | |
+5.29% | 61.9B | |
+10.12% | 42.86B | |
+7.95% | 40.84B | |
+18.92% | 34.58B | |
+5.88% | 25.46B | |
-5.25% | 22.13B |
- Stock Market
- Equities
- IPO Stock
- News IP Group Plc
- Enterprise Therapeutics Ltd announced that it has received £26 million in funding from Versant Venture Management, LLC, Novartis Venture Funds, Forbion Capital Partners B.V., Epidarex Capital, IP Group Plc, Panakès Partners SGR SpA